Board of Directors

Board of Directors

Mikael Orum, Board Member

Mikael is Founder and Partner of Ventac Partners and has 40 years of executive experience in finance and biotech. He is currently CEO and Chairman (and co-founder) of Avexxin AS, Co-founder and Board Member of Idogen AB, which listed on Swedish Aktietorget in 2015, and Chairman of RhoVac AB, which listed on Swedish Aktietorget in 2016. He has raised $100Mio in risk capital for biotech and pharma ventures. He has been responsible for multiple licensing deals in USA, Europe, Japan and China. He was co-founder and CEO of Exiqon, which was listed on Nasdaz OMX in 2007 from 1995-2002. He was co-founder of Santaris Pharma which sold to Hoffman la-Roche in 2014 for $450 Mio. Mikael has business and legal educations from Copenhagen Business College, Danish Bankers Academy, Copenhagen Business School and Copenhagen University.

Morten Sogaard, Board Member

Dr. Morten Søgaard is the Vice President and Head of Target Sciences at Pfizer, Inc. He oversees human genetics, functional genomics, computational biology and innovative target exploration academic networks (ITENs) capabilities for identifying and validating novel targets in areas of emerging science of interest to Pfizer R&D. Morten also oversees Pfizer’s companion diagnostic development organization and (before externalizing it) Pfizer’s biobank. He in previous roles guided Pfizer’s investments in platform technologies and oversaw platform technology and oncology licensing (to phase II) and co-led several Pfizer-wide strategy initiatives on Precision Medicine, AI, Gene Therapy. Morten has a Ph.D. in Biochemistry from the University of Copenhagen.

Mikael B. Waitzkin, Board Member

Michael B. Waitzkin is the Deputy Director of the Duke Initiative for Science & Society and teaches courses in the graduate, law and medical schools on issues of science law, policy and ethics. Before coming to Duke, he practiced law in the District of Columbia for 35 years and has extensive experience in advising the biomedical research community on issues relating to legal and regulatory strategy and ethics. He served as Special Counsel to the President in the White House Counsel’s Office. He attended the University of Virginia (BA 1971; Phi Beta Kappa, Echols Scholar), Stanford Law School (JD 1974) and Yale Law School (LLM 1975, Commonwealth Fellow in Law, Science and Medicine).